Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs)

Texto completo
Autor(es):
Campanella, Nathalia C. [1] ; de Oliveira, Antonio T. [2] ; Scapulatempo-Neto, Cristovam [3, 1] ; Guimaraes, Denise P. [1, 4] ; Reis, Rui M. [1, 5]
Número total de Autores: 5
Afiliação do(s) autor(es):
[1] Barretos Canc Hosp, Mol Oncol Res Ctr, Barretos, SP - Brazil
[2] Barretos Canc Hosp, Dept Upper Surg, Barretos, SP - Brazil
[3] Barretos Canc Hosp, Dept Pathol, Barretos, SP - Brazil
[4] Barretos Canc Hosp, Dept Endoscopy, Barretos, SP - Brazil
[5] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Braga - Portugal
Número total de Afiliações: 5
Tipo de documento: Artigo de Revisão
Fonte: Recent Patents on Anti-Cancer Drug Discovery; v. 8, n. 3, p. 288-297, SEP 2013.
Citações Web of Science: 6
Resumo

Gastrointestinal stromal tumors (GISTs) owe their development to the activating mutations in mast/stem cell growth factor receptor (KIT) or platelet-derived growth factor receptor A (PDGFRA) oncogenes. Both these KIT and PDGFRA oncogenes are members of the type III transmembrane receptor tyrosine kinase family that stimulates intracellular signaling pathways controlling cell proliferation, adhesion, apoptosis, survival, and differentiation. The presence and type of KIT/PDGFRA mutations help to predict the imatinib mesylate therapy, a selective tyrosine kinase inhibitor. Moreover, there is reported a small proportion of wild-type GISTs for both KIT and PDGFRA genes, and tumors more often acquire secondary mutations on KIT, that results into imatinib resistance. New patents to the GISTs imatinib resistant have recently been introduced. At present, sunitinib, is prescribed as second line therapy for patients with imatinib-resistant or imatinib-intolerant GIST, and a number of other drugs, such as masitinib and valatinib, are in the pipeline. The present research focuses on GISTs diagnostic, prognostic and therapeutic biomarkers and addresses the development of novel patents for the treatment of these patients. (AU)

Processo FAPESP: 12/01732-2 - Estudo da instabilidade de microssatélite e potenciais genes alvos em GISTs.
Beneficiário:Nathália Cristina Campanella
Linha de fomento: Bolsas no Brasil - Mestrado